Eplerenone

SKU: orb1310957

Description

Eplerenone

Research Area

Metabolism Research

Key Properties

• CAS Number: 107724-20-9
• MW: 414.49
• Purity: 99.84%
• Formula: C₂₄H₃₀O₆
• SMILES: C[C@@]12[C@]34[C@]([C@]5([C@](C)(C[C@]3(O4)[H])[C@@]6(CC5)CCC(=O)O6)[H])([C@H](C(OC)=O)CC1=CC(=O)CC2)[H]
• Target: Glucocorticoid Receptor,Endogenous Metabolite
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.41 mM);DMSO:7.14 mg/mL (17.23 mM)

Bioactivity

• Target IC50:
  Aldosterone:0.36 μM
• In Vitro:
  Eplerenone increases total vascular and luminal areas in swine without affecting the endothelial area. In canine models, it significantly reduces left ventricular end-diastolic wall stress. Eplerenone attenuates the rise in pulse pressure due to aldosterone (Aldo) in rats, normalizing the wall stress curve, mean cross-sectional area, and EIIIA fibronectin levels in Aldo-salt hypertensive rats. The compound upregulates diminished endothelial nitric oxide synthase mRNA in Dahl salt-sensitive hypertensive (DS) rats, markedly improving glomerulosclerosis and proteinuria. In mice, daily administration of 200 mg/kg of Eplerenone significantly lowers systolic and diastolic blood pressures compared to controls and increases serum phosphatase activity.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

aldosterone, cardiovascular (CV), atherosclerosis, CGP 30083, CGP30083, CGP-30083, chronic systolic heart failure (HF), Endogenous Metabolite, Inhibitor, hypertension, Glucocorticoid Receptor, GlucocorticoidReceptor, Eplerenone, Epoxymexrenone, Mineralocorticoid Receptor, MRA, inhibit, specific, SC 66110, SC66110, SC-66110

Compound Identifiers

PubChem CID

443872